scholarly journals Multi-omic brain and behavioral correlates of cell-free fetal DNA methylation in macaque maternal obesity models

2021 ◽  
Author(s):  
Benjamin I Laufer ◽  
Yu Hasegawa ◽  
Zhichao Zhang ◽  
Casey E Hogrefe ◽  
Laura A Del Rosso ◽  
...  

Maternal obesity during pregnancy is associated with neurodevelopmental disorder (NDD) risk. We utilized integrative multi-omics to examine maternal obesity effects on offspring neurodevelopment in rhesus macaques by comparison to lean controls and two interventions. Differentially methylated regions (DMRs) from longitudinal maternal blood-derived cell-free fetal DNA (cffDNA) significantly overlapped with DMRs from infant brain. The DMRs were enriched for neurodevelopmental functions, methylation-sensitive developmental transcription factor motifs, and human NDD DMRs identified from brain and placenta. Brain and cffDNA methylation levels from a large region overlapping mir-663 correlated with maternal obesity, metabolic and immune markers, and infant behavior. A DUX4 hippocampal co-methylation network correlated with maternal obesity, infant behavior, infant hippocampal lipidomic and metabolomic profiles, and maternal blood measurements of DUX4 cffDNA methylation, cytokines, and metabolites. Ultimately, maternal obesity altered infant brain and behavior, and these differences were detectable in pregnancy through integrative analyses of cffDNA methylation with immune and metabolic biomarkers.

2014 ◽  
Vol 34 (4) ◽  
pp. 341-344 ◽  
Author(s):  
Jacob Mørup Schlütter ◽  
Lotte Hatt ◽  
Cathrine Bach ◽  
Ida Kirkegaard ◽  
Steen Kølvraa ◽  
...  

2004 ◽  
Vol 58 (1) ◽  
pp. 57-60 ◽  
Author(s):  
Xiao Xi Zhao ◽  
Nobuhiro Suzumori ◽  
Yasuhiko Ozaki ◽  
Takeshi Sato ◽  
Kaoru Suzumori

2016 ◽  
Vol 5 (2) ◽  
pp. 89 ◽  
Author(s):  
I Nyoman Hariyasa Sanjaya ◽  
Tjok Gde Agung Suwardewa ◽  
I G Kamasan N. Arijana

2012 ◽  
Vol 36 (5) ◽  
Author(s):  
Markus Stumm ◽  
Rolf-Dieter Wegner ◽  
Wera Hofmann

ZusammenfassungDie zellfreie fetale DNA (cff-DNA) im mütterlichen Blut bietet viele neue Möglichkeiten der pränatalen genetischen Diagnostik. Im Gegensatz zu den etablierten invasiven Techniken der Chorionzottenbiopsie (CVS) und der Amniozentese (AC), die beide mit einem spezifischen Risiko (0,5–1%) einer eingriffsbedingten Fehlgeburt einhergehen, ist die Grundlage für die Gewinnung der cff-DNA eine einfache venöse Blutentnahme der Mutter, die keinerlei Risiko für den Embryo oder Feten darstellt. Damit bietet die cff-DNA die Möglichkeit einer risikofreien genetischen Diagnostik von bestehenden Schwangerschaften. Molekulargenetische Techniken werden schon seit längerer Zeit zum qualitativen Nachweis von spezifischen fetalen Sequenzen, wie paternal vererbten oder neu entstandenen (de novo) Mutationen, eingesetzt. Durch den Einsatz digitaler PCR und Next-Generation-Sequencing (NGS) Technologien gelingt mittlerweile aber auch der sichere quantitative Nachweis von mutierten Allelen sowie von klinisch relevanten Aneuploidien (Trisomie 13, 18 und 21) aus fetaler DNA im mütterlichen Blut.


2013 ◽  
Vol 21 (2) ◽  
pp. 84-90 ◽  
Author(s):  
Kerry Oxenford ◽  
Madhavi Karunaratna ◽  
Melissa Hill ◽  
Sally Taffinder ◽  
Professor Lyn Chitty

ISRN Genetics ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-10
Author(s):  
Monisha Banerjee ◽  
Deepika Misra

Invasive prenatal diagnosis (PND) holds a multitude of psychological considerations for women, their partners, family and community as a whole. Earlier, the non-invasive screening methods for certain disorders were serum analytes or ultrasound with low sensitivity and high false positivity. The discovery of fetal DNA in maternal plasma has opened up an approach for noninvasive PND (NIPD). Presence of fetal cells and cell-free fetal DNA (cffDNA) in the blood of pregnant women has been accepted universally and constant efforts are being made to enrich fetal DNA from maternal blood/plasma. Real-time quantitative polymerase chain reaction (qrt-PCR) has enabled fetal DNA to serve as a marker for chromosomal abnormalities, for example, trisomy 21, preterm labor, and preeclampsia. In India, PND is provided in few centers since invasive methods require trained gynecologists, this limits investigation and therefore NIPD with cffDNA from mother's blood will revolutionize fetal medicine. The present paper deals with the latest developments in procurement of cffDNA, the probable source and enrichment of fetal DNA in maternal plasma, and the current status of its detection methodologies, applications, and its potential to be used as a powerful diagnostic tool.


JAMA ◽  
2004 ◽  
Vol 291 (9) ◽  
pp. 1135 ◽  
Author(s):  
Joe Leigh Simpson ◽  
Farideh Bischoff

Sign in / Sign up

Export Citation Format

Share Document